Integra LifeSciences price target lowered to $40 from $47 at Wells Fargo

Wells Fargo analyst Shagun Singh lowered the firm’s price target on Integra LifeSciences to $40 from $47 and keeps an Equal Weight rating on the shares. Underlying growth ex-Boston was strong at 7.1% and progress in addressing the Boston facility and returning to the market remains on track with good visibility, the firm says. Lots to digest again, but Wells were surprised to see the stock move down.